Acute TTP relapse in trial patients receiving rituximab compared with historic controls. Kaplan-Meier curve of relapse-free period of historical controls compared with patients who received rituximab. Over a 49-month period, more than half of the historical control patients had a further acute TTP episode. This was significantly reduced in the rituximab group.